“What we found was really astonishing for us. After we inhibited the galectin1 protein, the brain tumors simply didn't grow for several months," says Arezu Jahani-Asl, an Associate Professor of Medicine at McGill University. "To improve patient response to therapy, we must exploit these newly identified vulnerabilities in cancer stem cells."
News 
Market Data 
Discover 
